Breast Cancer
Conditions
Interventions
Group 1:palbociclib combined with letrozole
Group 2:epirubicin combined with cyclophosphamide and sequential docetaxel
Sponsors
Shengjing Hospital of China Medical University
Eligibility
Sex/Gender
Female
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. pathological examination confirms estrogen receptor positive, and Ki67 =T3, or lymph node stage >=N2, or ipsilateral upper extremity edema or the extent of lesions exceeds the scope of radical surgery; 4. Karnofsky functional status score >=70; 5. normal findings of blood examination, normal liver and kidney functions, and basically normal electrocardiogram results before chemotherapy; 6. aged 18–70 years old.
Exclusion criteria
Exclusion criteria: 1. history of anti-tumor treatment; 2. inflammatory breast cancer or occult breast cancer; 3. stage IV breast cancer; 4. history of other malignant tumors; 5. severe vital organ dysfunction, such as heart, liver and kidney or poor constitution cannot tolerate chemotherapy, or the treatment plan change due to intolerance during chemotherapy; 6. cannot comply with the treatment because of mental and neurological diseases; 7. dexamethasone contraindications or severe allergies to any drug in NAC; 8. receiving NAC, but it is judged to be ineffective after two cycles of treatment, and other programs are forced to be used or chemotherapy is stopped to receive surgery; 9. participation in other clinical trials.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Efficacy; | — |
Secondary
| Measure | Time frame |
|---|---|
| Breast-conserving rate;Operable rate;Ki67 expression in tumor tissues;Miller-Payne grading system;Preoperative endocrine prognostic index;Progression-free survival;Overall survival;Adverse events; | — |
Countries
China
Contacts
Public ContactCaigang Liu
Shengjing Hospital of China Medical University
Outcome results
None listed